Some of today’s large language models may be more effective communicators than providers when it comes to explaining interventional radiology procedures.
The U.S. Food and Drug Administration highlighted concerns about "data drift," which can potentially lead to performance degradation, bias or reduced reliability.
Crafting these materials is typically left up to radiologists who draw from their own educational and clinical experiences, but the process is time consuming and can incur significant costs.
An updated version of Heartflow's Plaque Analysis platform has gained FDA clearance. In addition, the company announced that Cigna will cover the platform going forward.
Several groups collaborated on the document, which is designed to help clinicians provide high-quality, consistent care when using flurpiridaz during cardiac PET imaging exams.
